Three caveats to the following opinion; those being ... "This is Celgene after all" is well put and holds sway. No negative news on catalysts. No macro driven market meltdowns.
If the catalysts come in, the price goes up by year's end - either as independant company or an acquired one.
- Catalysts remove "one trick pony issue, confirms earnings acceleration and puts $10 a share earnings in place three year's out. That puts a conservative projected 2015 share price at $130 to $140 with roughly market P/E of 13 to 14. If Celgene's pps at the close of 2012 is at today's level or lower, it will be taken out at $100 (40% premium).
Time will tell and my basis - along with confidence in new team - for my optimism.
Now to outside spring clean-up.
